CN111537461A - A method for detecting adenine and guanine in solution with boron cluster gold nanoparticles - Google Patents
A method for detecting adenine and guanine in solution with boron cluster gold nanoparticles Download PDFInfo
- Publication number
- CN111537461A CN111537461A CN202010467209.4A CN202010467209A CN111537461A CN 111537461 A CN111537461 A CN 111537461A CN 202010467209 A CN202010467209 A CN 202010467209A CN 111537461 A CN111537461 A CN 111537461A
- Authority
- CN
- China
- Prior art keywords
- solution
- adenine
- guanine
- gold
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 239000010931 gold Substances 0.000 title claims abstract description 52
- 229910052737 gold Inorganic materials 0.000 title claims abstract description 52
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229930024421 Adenine Natural products 0.000 title claims abstract description 38
- 229960000643 adenine Drugs 0.000 title claims abstract description 38
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 21
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 229910052796 boron Inorganic materials 0.000 title claims abstract description 12
- 239000000243 solution Substances 0.000 claims abstract description 51
- 238000001514 detection method Methods 0.000 claims abstract description 26
- 239000002253 acid Substances 0.000 claims abstract description 16
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- 150000001638 boron Chemical class 0.000 claims abstract description 9
- 239000000523 sample Substances 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 7
- 238000000862 absorption spectrum Methods 0.000 claims abstract description 6
- 239000012488 sample solution Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 11
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 150000003212 purines Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 235000005811 Viola adunca Nutrition 0.000 description 2
- 240000009038 Viola odorata Species 0.000 description 2
- 235000013487 Viola odorata Nutrition 0.000 description 2
- 235000002254 Viola papilionacea Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000016839 purine metabolism disease Diseases 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
Landscapes
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明适用于纳米金的识别检测领域,提供一种硼簇纳米金检测溶液中腺嘌呤和鸟嘌呤的方法。先按常规工艺制备硼簇还原的纳米金,并将其稀释,得到稀释后的溶液;然后用酸调节稀释后溶液的pH,再加入样品水溶液,即可实现对腺嘌呤的特异性识别;若体系中不存在腺嘌呤,则继续加酸调节溶液的pH,即可实现对鸟嘌呤的特异性识别;最后对所得纳米金样品溶液进行紫外可见吸收光谱扫描,根据纳米金A650/A525的信号强弱,即可对腺嘌呤或鸟嘌呤的浓度加以测定。本发明相较于传统检测方法具有方便快捷、检测成本低、原料损失少以及对仪器要求低等优点。
The invention is suitable for the identification and detection field of nano-gold, and provides a method for detecting adenine and guanine in a solution of boron cluster nano-gold. First, prepare the gold nanoparticles reduced by boron clusters according to the conventional process, and dilute it to obtain the diluted solution; then adjust the pH of the diluted solution with acid, and then add the sample aqueous solution to realize the specific recognition of adenine; There is no adenine in the system, then continue to add acid to adjust the pH of the solution, and then the specific recognition of guanine can be realized; finally, the obtained nano-gold sample solution is subjected to ultraviolet-visible absorption spectrum scanning, according to the nano-gold A 650 /A 525 . The signal strength can be used to measure the concentration of adenine or guanine. Compared with the traditional detection method, the invention has the advantages of convenience and quickness, low detection cost, less loss of raw materials, and low requirements for instruments.
Description
技术领域technical field
本发明属于纳米金的识别检测领域,尤其涉及一种硼簇纳米金检测溶液中腺嘌呤和鸟嘌呤的方法。The invention belongs to the field of identification and detection of nano-gold, in particular to a method for detecting adenine and guanine in a solution of boron cluster nano-gold.
背景技术Background technique
嘌呤是人类健康的重要贡献者,在供应能量、组成辅酶、调节代谢等方面起着至关重要的作用。腺嘌呤旧称维生素B4,是DNA和RNA的重要组成部分,它能促进白细胞增生,常被用于治疗白细胞减少症和急性粒细胞减少症等,除此之外,它还被用于生产维生素B4、植物生长激素等药物,以及生化研究。鸟嘌呤是一种有机碱,广泛存在于动植物体内,也是构成核酸的重要碱基,常被应用于制备抗病毒药物阿昔洛韦的中间体,制备咖啡因等药物,以及生化研究。Purines are important contributors to human health and play a crucial role in supplying energy, forming coenzymes, and regulating metabolism. Adenine, formerly known as vitamin B 4 , is an important part of DNA and RNA. It can promote the proliferation of white blood cells and is often used to treat leukopenia and acute neutropenia. In addition, it is also used to produce vitamins. B 4 , plant growth hormone and other drugs, as well as biochemical research. Guanine is an organic base that exists widely in animals and plants, and is also an important base that constitutes nucleic acids. It is often used in the preparation of intermediates of antiviral drug acyclovir, preparation of caffeine and other drugs, and biochemical research.
人体中可以依靠自身合成腺嘌呤和鸟嘌呤,食物中也含有大量的嘌呤类化合物。但是,人体吸收的嘌呤却并不是越多越好。嘌呤在人体内分解代谢变为尿酸,随尿排出。若人体内摄入过多的嘌呤,往往会出现嘌呤代谢紊乱,尿酸排泄障碍,从而引起高尿酸血症,也就是我们常说的痛风。因此,痛风患者尤其应当控制高嘌呤的摄入,他们所接触的食物药物等中嘌呤含量的简捷测定显得尤为重要。The human body can rely on its own synthesis of adenine and guanine, and food also contains a lot of purine compounds. However, the more purines the body absorbs, the better. Purines are catabolized in the human body into uric acid, which is excreted in urine. If the human body takes in too much purine, purine metabolism disorder and uric acid excretion disorder will often occur, resulting in hyperuricemia, which is what we often call gout. Therefore, gout patients especially should control the intake of high purine, and the simple determination of purine content in the food and drugs they come into contact with is particularly important.
纳米金比色法是一种基于肉眼即可观察现象的快速便捷的检测方法。当金纳米粒子在溶液中呈分散状态时,溶液呈酒红色,而当金纳米粒子在溶液中呈团聚状态时,溶液则呈蓝紫色,这就使得纳米金比色法可以很方便地运用于样品的定性分析。同时,这种颜色变化还会带来紫外可见吸收光谱上最大吸收峰的位移(从525nm附近到650nm附近),并且样品在650nm附近与525nm附近的吸光度比值在一定范围内与样品中待测物的浓度呈正比,这就为纳米金比色法用于样品的定量分析提供了基础。但是纳米金比色法的运用往往需要在纳米金表面连接一些能与待测物质相互作用的识别基团,这个过程通常会带来复杂的修饰过程,以及原料的损失浪费。Nanogold colorimetry is a fast and convenient detection method based on phenomena that can be observed with the naked eye. When the gold nanoparticles are dispersed in the solution, the solution is wine red, and when the gold nanoparticles are agglomerated in the solution, the solution is blue-violet, which makes the nano-gold colorimetry can be easily applied to Qualitative analysis of samples. At the same time, this color change will also bring about the shift of the maximum absorption peak on the ultraviolet-visible absorption spectrum (from around 525nm to around 650nm), and the ratio of the absorbance of the sample around 650nm to around 525nm is within a certain range and the object to be tested in the sample. The concentration of gold nanoparticles is proportional to the concentration, which provides the basis for the quantitative analysis of samples by the nano-gold colorimetric method. However, the application of nanogold colorimetry often requires the connection of some recognition groups that can interact with the substance to be tested on the surface of gold nanoparticles, which usually leads to complex modification processes and loss of raw materials.
发明内容SUMMARY OF THE INVENTION
鉴于上述问题,本发明的目的在于提供一种硼簇纳米金检测溶液中腺嘌呤和鸟嘌呤的方法,旨在解决现有检测方法存在的操作繁琐、检测成本高、原料损失多以及对仪器要求高等技术问题。In view of the above-mentioned problems, the object of the present invention is to provide a kind of boron cluster nano-gold detection method for adenine and guanine in solution, aiming to solve the complicated operation, high detection cost, many loss of raw materials and requirements for instruments existing in the existing detection method Advanced technical issues.
所述方法包括如下步骤:The method includes the following steps:
步骤S1:按常规工艺制备硼簇还原的纳米金,并将其稀释,得到稀释后的溶液;Step S1: prepare the gold nanoparticles reduced by boron clusters according to a conventional process, and dilute it to obtain a diluted solution;
步骤S2:用酸调节稀释后溶液的pH,再加入样品水溶液,即可实现对腺嘌呤的特异性识别;Step S2: adjusting the pH of the diluted solution with acid, and then adding the sample aqueous solution, the specific recognition of adenine can be realized;
步骤S3:若体系中不存在腺嘌呤,则继续加酸调节溶液的pH,即可实现对鸟嘌呤的特异性识别;Step S3: if there is no adenine in the system, continue to add acid to adjust the pH of the solution, so as to realize the specific recognition of guanine;
步骤S4:对所得纳米金样品溶液进行紫外可见吸收光谱扫描,根据纳米金A650/A525的信号强弱,即可对腺嘌呤或鸟嘌呤的浓度加以测定。Step S4: Scanning the obtained nano-gold sample solution by ultraviolet-visible absorption spectrum, according to the signal strength of nano-gold A 650 /A 525 , the concentration of adenine or guanine can be determined.
优选的,步骤S1中,采用Cs2B12H12作为还原剂和稳定剂,按照摩尔比1:1的量将Cs2B12H12加入到氯金酸溶液中,在25℃下搅拌30min,即可得到硼簇还原的纳米金。Preferably, in step S1, Cs 2 B 12 H 12 is used as reducing agent and stabilizer, Cs 2 B 12 H 12 is added to the chloroauric acid solution in a molar ratio of 1:1, and stirred at 25° C. for 30 min , the gold nanoparticles reduced by boron clusters can be obtained.
优选的,Cs2B12H12和氯金酸在溶液中的浓度均为0.4mM,且溶剂为水。Preferably, the concentrations of Cs 2 B 12 H 12 and chloroauric acid in the solution are both 0.4 mM, and the solvent is water.
优选的,步骤S2中,溶液pH的范围为2.0-2.5,样品水溶液的浓度为0-200μM。Preferably, in step S2, the pH of the solution is in the range of 2.0-2.5, and the concentration of the sample aqueous solution is 0-200 μM.
优选的,步骤S3中,溶液pH的范围为1.8-2.0。Preferably, in step S3, the pH of the solution is in the range of 1.8-2.0.
本发明提供一种硼簇纳米金检测溶液中腺嘌呤和鸟嘌呤的方法,具有以下优点:The invention provides a method for detecting adenine and guanine in a solution of boron cluster nano-gold, which has the following advantages:
1.纳米金合成采用一步法,合成过程简单,原料损失少;1. Nano-gold synthesis adopts one-step method, the synthesis process is simple, and the loss of raw materials is small;
2.检测前期准备工作简单,配好溶液即可进行定性检测;2. The preparatory work for the detection is simple, and the qualitative detection can be carried out after the solution is prepared;
3.定性检测过程简便,现象肉眼可见,易于观测;3. The qualitative detection process is simple, the phenomenon is visible to the naked eye, and it is easy to observe;
4.定量检测对仪器要求低,常规紫外可见分光光度计即可完成;4. Quantitative detection requires low instrument requirements, and can be completed by conventional UV-Vis spectrophotometer;
5.对两种嘌呤的检测可以实现分步检测,无需复杂的预处理操作,仅需调节溶液pH以及记录变色时间。5. The detection of two kinds of purines can realize step-by-step detection, without complex pretreatment operation, only need to adjust the pH of the solution and record the discoloration time.
附图说明Description of drawings
图1为本发明实施例一中pH=2.0条件下0min和10min的紫外可见吸收光谱A650/A525对碱基种类的柱状图(碱基浓度为200μM);Fig. 1 is the histogram of the UV-Vis absorption spectrum A 650 /A 525 pair base species under the condition of pH=2.0 for 0 min and 10 min in Example 1 of the present invention (base concentration is 200 μM);
图2为本发明实施例二中pH=2.0条件下0h和0.5h的紫外可见吸收光谱A650/A525对盐浓度的曲线图(碱基浓度为40μM);Fig. 2 is the curve diagram of UV-Vis absorption spectrum A 650 /A 525 versus salt concentration at pH=2.0 for 0 h and 0.5 h in Example 2 of the present invention (base concentration is 40 μM);
图3为本发明实施例三中pH=2.0条件下0h的紫外可见吸收光谱A650/A525对腺嘌呤浓度的曲线图(碱基浓度为20μM);3 is a graph of the UV-Vis absorption spectrum A 650 /A 525 at pH=2.0 for 0 h versus adenine concentration in Example 3 of the present invention (base concentration is 20 μM);
图4为本发明实施例三中pH=2.0条件下1h的紫外可见吸收光谱A650/A525对鸟嘌呤浓度的曲线图(碱基浓度为20μM);4 is a graph showing the UV-Vis absorption spectrum A 650 /A 525 for 1 h under the condition of pH=2.0 in Example 3 of the present invention versus guanine concentration (base concentration is 20 μM);
图5为本发明实施例四中pH=2.0条件下0h不同碱基体系的紫外可见吸收光谱图(碱基浓度均为20μM);Fig. 5 is the UV-Vis absorption spectrogram of different base systems at 0 h under the condition of pH=2.0 in Example 4 of the present invention (base concentrations are all 20 μM);
图6为本发明实施例四中pH=2.0条件下1h不同碱基体系的紫外可见吸收光谱图(碱基浓度均为20μM)。FIG. 6 is the UV-Vis absorption spectra of different base systems under the condition of pH=2.0 for 1 h in Example 4 of the present invention (base concentrations are all 20 μM).
具体实施方式Detailed ways
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。In order to make the objectives, technical solutions and advantages of the present invention clearer, the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention, but not to limit the present invention.
一种硼簇纳米金检测溶液中腺嘌呤和鸟嘌呤的方法,所述方法包括如下步骤:A boron cluster nano-gold detection method for adenine and guanine in a solution, the method comprising the steps of:
步骤S1:按常规工艺制备硼簇还原的纳米金,并将其稀释,得到稀释后的溶液。Step S1: Prepare the gold nanoparticles reduced by boron clusters according to the conventional process, and dilute it to obtain a diluted solution.
本步骤中,在制备硼簇还原的纳米金时,采用Cs2B12H12作为还原剂和稳定剂,按照摩尔比1:1的量将Cs2B12H12加入到氯金酸溶液中,在25℃下搅拌30min,即可得到硼簇还原的纳米金。其中Cs2B12H12和氯金酸在体系中的浓度均为0.4mM,且溶剂为水;将纳米金进行稀释时,根据检测仪器的型号类型进行稀释2-10倍,作为一种优选,本实验中选择稀释4-5倍。In this step, when preparing gold nanoparticles reduced by boron clusters, Cs 2 B 12 H 12 is used as reducing agent and stabilizer, and Cs 2 B 12 H 12 is added to the chloroauric acid solution in a molar ratio of 1:1. , and stirred at 25 °C for 30 min to obtain gold nanoparticles reduced by boron clusters. The concentrations of Cs 2 B 12 H 12 and chloroauric acid in the system are both 0.4 mM, and the solvent is water; when diluting the nano-gold, it should be diluted 2-10 times according to the type of the detection instrument, as a preferred , choose to dilute 4-5 times in this experiment.
步骤S2:用酸调节稀释后溶液的pH,再加入样品水溶液,即可实现对腺嘌呤的特异性识别。Step S2: The pH of the diluted solution is adjusted with acid, and then the sample aqueous solution is added to realize the specific recognition of adenine.
本步骤中,溶液pH的范围为2.0-2.5,调节溶液pH时只能用酸,过高浓度的缓冲溶液会带来过高的盐浓度,从而影响纳米金的稳定性,样品水溶液的浓度为0-200μM。In this step, the pH of the solution is in the range of 2.0-2.5, and only acid can be used to adjust the pH of the solution. Too high concentration of buffer solution will bring too high salt concentration, which will affect the stability of gold nanoparticles. The concentration of the sample aqueous solution is 0-200 μM.
步骤S3:若体系中不存在腺嘌呤,则继续加酸调节溶液的pH,即可实现对鸟嘌呤的特异性识别。Step S3: If there is no adenine in the system, continue to add acid to adjust the pH of the solution, so as to realize the specific recognition of guanine.
本步骤中,溶液pH的范围为1.8-2.0,调节溶液pH时只能用酸。In this step, the pH of the solution is in the range of 1.8-2.0, and only acid can be used to adjust the pH of the solution.
在对腺嘌呤和鸟嘌呤进行检测时,溶液的pH值不固定,在一定pH范围内均可完成检测,并且pH值越低,检测时间越短,但是这时其它碱基的干扰也越大。例如在pH=2.0时,腺嘌呤可以实现即配即测的快速检测,而鸟嘌呤的检测则根据鸟嘌呤的浓度需要10min甚至1h以上;而在pH<1.8时,鸟嘌呤可以实现快速检测,但一段时间后,胞嘧啶、胸腺嘧啶、尿嘧啶也会先后出现溶液颜色的变化。In the detection of adenine and guanine, the pH value of the solution is not fixed, and the detection can be completed within a certain pH range, and the lower the pH value, the shorter the detection time, but the interference of other bases is also greater at this time. . For example, when pH = 2.0, adenine can be quickly detected, and the detection of guanine requires 10 minutes or even more than 1 hour according to the concentration of guanine; and when pH < 1.8, guanine can be detected quickly. However, after a period of time, cytosine, thymine, and uracil will also change the color of the solution successively.
步骤S4:对所得纳米金样品溶液进行紫外可见吸收光谱扫描,根据纳米金A650/A525的信号强弱,即可对腺嘌呤或鸟嘌呤的浓度加以测定。Step S4: Scanning the obtained nano-gold sample solution by ultraviolet-visible absorption spectrum, according to the signal strength of nano-gold A 650 /A 525 , the concentration of adenine or guanine can be determined.
本步骤中,对所得纳米金样品溶液进行紫外可见吸收光谱扫描,在一定范围内,650nm和525nm处的吸光度比值与腺嘌呤或鸟嘌呤的浓度成正比。In this step, the obtained nano-gold sample solution is subjected to ultraviolet-visible absorption spectrum scanning, and within a certain range, the ratio of absorbance at 650 nm and 525 nm is proportional to the concentration of adenine or guanine.
为了说明本发明所述的技术方案,下面通过具体实施例来进行说明。In order to illustrate the technical solutions of the present invention, the following specific embodiments are used for description.
实施例一:Example 1:
将Cs2B12H12还原稳定的纳米金稀释4倍,用浓盐酸调节溶液pH分别为2.5、2.0和1.8,记录所用浓盐酸的体积。The Cs 2 B 12 H 12 reduction-stabilized gold nanoparticles were diluted 4 times, and the pH of the solution was adjusted to 2.5, 2.0, and 1.8 with concentrated hydrochloric acid, and the volume of the concentrated hydrochloric acid used was recorded.
另取Cs2B12H12还原稳定的纳米金稀释3倍,加入上步相同体积比的浓盐酸,再加入原纳米金溶液1倍体积的腺嘌呤、鸟嘌呤、胞嘧啶、胸腺嘧啶、尿嘧啶的水溶液(碱基最终浓度为200μM),记录纳米金的变色时间,结果如下表所示。In addition, take the Cs 2 B 12 H 12 reduction-stabilized gold nanoparticles and dilute it by 3 times, add concentrated hydrochloric acid in the same volume ratio of the previous step, and then add 1 volume of the original gold nanoparticles solution of adenine, guanine, cytosine, thymine, urine The aqueous solution of pyrimidine (the final concentration of base is 200 μM), the discoloration time of gold nanoparticles was recorded, and the results are shown in the following table.
对体系进行紫外可见吸收光谱扫描,结果如图1所示。The system was scanned by UV-Vis absorption spectrum, and the results are shown in Figure 1.
实施例二:Embodiment 2:
将Cs2B12H12还原稳定的纳米金稀释2倍,加入实施例1中调节pH为2.0的相同体积比的浓盐酸以及不同体积的NaCl水溶液,并用去离子水定容至溶液总体积为原纳米金溶液的3倍。最后加入原纳米金溶液1倍体积的去离子水或腺嘌呤水溶液、鸟嘌呤水溶液。其中在盐浓度小于70mM时,不加嘌呤的体系没有发生明显变色,而加入腺嘌呤或鸟嘌呤的体系在不同时间后均出现了颜色改变。对体系进行紫外可见吸收光谱扫描,结果如图2所示。Dilute the Cs 2 B 12 H 12 reduction-stabilized gold nanoparticles by 2 times, add the same volume ratio of concentrated hydrochloric acid and different volumes of NaCl aqueous solution adjusted to pH 2.0 in Example 1, and use deionized water to dilute to a total solution volume of 3 times that of the original nano-gold solution. Finally, 1 volume of the original gold nanoparticles solution was added with deionized water or adenine aqueous solution and guanine aqueous solution. When the salt concentration was less than 70 mM, the system without purine did not change color obviously, while the system with adenine or guanine added color changed after different time. The system was scanned by UV-Vis absorption spectrum, and the results are shown in Figure 2.
实施例三:Embodiment three:
将Cs2B12H12还原稳定的纳米金稀释3倍,加入浓盐酸和NaCl水溶液,以及不同体积的腺嘌呤或鸟嘌呤水溶液,并用去离子水定容,使最终体系中的纳米金稀释4倍,NaCl浓度为70mM,体系pH为2.0,腺嘌呤浓度为0-10μM,鸟嘌呤浓度为0-30μM。在0h和1h时对体系进行紫外可见吸收光谱扫描。其中在0h时,在0.01-1μM范围内,紫外可见吸收光谱A650/A525与腺嘌呤的浓度呈正比;在1h时,在0.01-5μM范围内,紫外可见吸收光谱A650/A525与鸟嘌呤的浓度呈正比。结果如图3和图4所示。Dilute the Cs 2 B 12 H 12 reduction-stabilized gold nanoparticles by 3 times, add concentrated hydrochloric acid and NaCl aqueous solutions, and different volumes of adenine or guanine aqueous solutions, and make up with deionized water to dilute the gold nanoparticles in the final system by 4 times, the NaCl concentration was 70 mM, the pH of the system was 2.0, the adenine concentration was 0-10 μM, and the guanine concentration was 0-30 μM. At 0h and 1h, the system was scanned by UV-Vis absorption spectrum. Among them, at 0h, in the range of 0.01-1μM, the UV-Vis absorption spectrum A 650 /A 525 is proportional to the concentration of adenine; at 1h, in the range of 0.01-5μM, the UV-Vis absorption spectrum A 650 /A 525 is proportional to the concentration of adenine. The concentration of guanine is proportional. The results are shown in Figures 3 and 4.
实施例四:Embodiment 4:
将Cs2B12H12还原稳定的纳米金稀释3倍,加入浓盐酸和NaCl水溶液,以及一定体积的各种碱基水溶液,并用去离子水定容,使最终体系中的纳米金稀释4倍,NaCl浓度为70mM,体系pH为2.0,各种碱基浓度均为20μM。其中在0h时,加入不含腺嘌呤的4种碱基的体系呈红色,加入5种碱基的体系呈蓝紫色;在1h时,加入不含鸟嘌呤的3种碱基的体系呈红色,加入4种碱基的体系呈蓝紫色。在0h和1h时对体系进行紫外可见吸收光谱扫描,结果如图5和图6所示。Dilute the Cs 2 B 12 H 12 reduction-stabilized gold nanoparticles by 3 times, add concentrated hydrochloric acid and NaCl aqueous solution, and a certain volume of various base aqueous solutions, and dilute the volume with deionized water to dilute the gold nanoparticles in the final system by 4 times. , the NaCl concentration was 70 mM, the pH of the system was 2.0, and the concentrations of various bases were 20 μM. Among them, at 0h, the system with 4 kinds of bases without adenine is red, and the system with 5 kinds of bases is blue-violet; at 1h, the system with 3 kinds of bases without guanine is red, The system with the addition of 4 bases is blue-purple. The UV-Vis absorption spectrum of the system was scanned at 0h and 1h, and the results are shown in Figures 5 and 6.
在本发明实施例中,利用硼簇的两个永久负电荷与嘌呤在酸性条件下质子化的N之间的静电相互作用,使纳米金发生团聚,从而引起溶液颜色的变化,达到快速便捷地识别检测并定量的目的。同时,由于腺嘌呤、鸟嘌呤与硼簇作用的强度不一致,使得纳米金在不同酸性条件下的变色时间不一致,从而可以对两种嘌呤实现分步检测。本发明相较于传统检测方法具有方便快捷、检测成本低、原料损失少、对仪器要求低等优点。In the embodiment of the present invention, the electrostatic interaction between the two permanent negative charges of the boron cluster and the protonated N of the purine under acidic conditions is used to make the gold nanoparticles agglomerate, thereby causing the color of the solution to change, so as to achieve a fast and convenient Identify the purpose of detection and quantification. At the same time, due to the inconsistent strength of the interaction between adenine, guanine and boron clusters, the discoloration time of gold nanoparticles under different acidic conditions is inconsistent, so that the two purines can be detected step by step. Compared with the traditional detection method, the present invention has the advantages of convenience and quickness, low detection cost, less loss of raw materials, and low requirements for instruments.
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。The above descriptions are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements and improvements made within the spirit and principles of the present invention shall be included in the protection of the present invention. within the range.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010467209.4A CN111537461A (en) | 2020-05-28 | 2020-05-28 | A method for detecting adenine and guanine in solution with boron cluster gold nanoparticles |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010467209.4A CN111537461A (en) | 2020-05-28 | 2020-05-28 | A method for detecting adenine and guanine in solution with boron cluster gold nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111537461A true CN111537461A (en) | 2020-08-14 |
Family
ID=71976453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010467209.4A Pending CN111537461A (en) | 2020-05-28 | 2020-05-28 | A method for detecting adenine and guanine in solution with boron cluster gold nanoparticles |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111537461A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015002569A1 (en) * | 2013-07-03 | 2015-01-08 | Общество С Ограниченной Ответственностью "Синтегал" | Method for immobilizing therapeutic drugs on the surface of detonation nanodiamonds |
CN106610380A (en) * | 2015-10-26 | 2017-05-03 | 华东理工大学 | Method used for rapid detection of xanthine |
CN107300551A (en) * | 2017-06-13 | 2017-10-27 | 中国科学院上海应用物理研究所 | A kind of melamine visible detection method based on nano Au particle color change |
CN107884399A (en) * | 2017-11-08 | 2018-04-06 | 北京化工大学 | For detecting the purine compound modified nano gold material of red blood cell, preparation method and kit |
CN108007923A (en) * | 2016-10-27 | 2018-05-08 | 武汉大学 | A kind of nanogold colorimetric method of quick detection lead ion |
-
2020
- 2020-05-28 CN CN202010467209.4A patent/CN111537461A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015002569A1 (en) * | 2013-07-03 | 2015-01-08 | Общество С Ограниченной Ответственностью "Синтегал" | Method for immobilizing therapeutic drugs on the surface of detonation nanodiamonds |
CN106610380A (en) * | 2015-10-26 | 2017-05-03 | 华东理工大学 | Method used for rapid detection of xanthine |
CN108007923A (en) * | 2016-10-27 | 2018-05-08 | 武汉大学 | A kind of nanogold colorimetric method of quick detection lead ion |
CN107300551A (en) * | 2017-06-13 | 2017-10-27 | 中国科学院上海应用物理研究所 | A kind of melamine visible detection method based on nano Au particle color change |
CN107884399A (en) * | 2017-11-08 | 2018-04-06 | 北京化工大学 | For detecting the purine compound modified nano gold material of red blood cell, preparation method and kit |
Non-Patent Citations (2)
Title |
---|
丁琼等: ""纳米金的制备及其在重金属离子检测中的应用——一个分析化学综合性研究型实验"", 《化学通报》 * |
张维敏等: "纳米金比色法测定6-巯基嘌呤", 《光谱实验室》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111175406B (en) | Method for simultaneously detecting multiple water-soluble vitamins in blood sample and application thereof | |
CN111175297B (en) | Method for measuring vitamin C content in fruits and vegetables by iodine turbidity method combined with infrared camera | |
CN103954722A (en) | Detection method aiming at trace urea in white spirit | |
CN111537461A (en) | A method for detecting adenine and guanine in solution with boron cluster gold nanoparticles | |
CN107589099A (en) | 6 purinethol detection methods and its kit based on gold nano cluster | |
CN114563495B (en) | Detection method of acetylcysteine and related substances thereof | |
CN108844933A (en) | A kind of fluorescence analysis method measuring artemislnin content | |
CN118112120A (en) | LC-MS (liquid crystal-mass spectrometry) -based method for simultaneously detecting 9 water-soluble vitamins in blood sample | |
CN110031526B (en) | Based on K2Fe4O7Dopamine enzyme-free sensor of electrode, preparation method and application thereof | |
CN110501402B (en) | An electrochemical sensor for ultrasensitive detection of sulfathiazole and its detection method | |
CN105466876B (en) | A kind of kit based on palladium nano-particles Visual retrieval Ismipur | |
CN115856060B (en) | Method for rapidly detecting binding rate of oligonucleotide drug and human and experimental animal plasma protein | |
Bian et al. | Spectrofluorimetric method for the determination of uric acid in human serum | |
CN108072717B (en) | Method for detecting arginine solution | |
US3822115A (en) | Method and reagent for uric acid determination | |
CN108827921B (en) | A room temperature phosphorescence detection method and application of lysozyme | |
CN111562227B (en) | Nanogold colorimetric method for detecting lysine | |
Holm | Automated colorimetric determination of penicillin in fermentation samples using a molybdoarsenic acid-mercuric chloride reagent | |
CN108051386B (en) | A method for accurate determination of chitosan content by ultraviolet spectrophotometry | |
Murrell et al. | DETERMINATION OF GLUCOSE IN FISH BLOOD: A MODIFICATION OF THE FOLIN–MALMROS MICROPROCEDURE | |
Patel | Semimicro method for determination of serum uric acid using EDTA—hydrazine | |
CN115166077A (en) | Double internal standard reagent for determination of enrofloxacin residue in aquatic product and detection method | |
Swenson et al. | Fluorometric estimation of surface associated microbial abundance | |
CN103994981A (en) | Method for rapid determination of aluminum ion content in honey product | |
CN114487193B (en) | Method for simultaneously measuring multiple water-soluble vitamins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200814 |
|
RJ01 | Rejection of invention patent application after publication |